Takeda Pharmaceutical Company
|Founded||Doshomachi, Osaka, Japan (June 12, 1781)|
|Headquarters||1-1, Doshomachi Yonchome, Chuo-ku, Osaka, Japan|
(Chairman of the Board)
(President & CEO)
|Revenue||¥1,557,267 million (FY 2012)[* 1]|
|¥122,505 million (FY 2012)[* 1]|
|¥131,244 million (FY 2012)[* 1]|
|Total assets||¥3,955,599 million (FY 2012)[* 1]|
|Total equity||¥2,223,359 million (FY 2012)[* 1]|
Number of employees
|Footnotes / references
Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Japan and Asia and a top 15 pharmaceutical company in the world. The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Millennium: The Takeda Oncology Company. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.
Takeda Pharmaceuticals was founded on June 12, 1781, and was incorporated on January 29, 1925.
In 1977, Takeda first entered the U.S. pharmaceutical market by developing a joint venture with Abbott Laboratories called TAP Pharmaceuticals. Through TAP Pharmaceuticals, Takeda and Abbott launched the blockbusters Lupron (leuprolide) in 1985 and Prevacid (lansoprazole) in 1995.
One of the firm's mainstay drugs is Actos, a compound in the thiazolidinedione class of drugs used in the treatment of type 2 diabetes. Launched in 1999, Actos has become the best-selling diabetes drug in the world with 4 billion USD in sales during the 2008 fiscal year.
In February 2005, Takeda announced its acquisition of San Diego, California, based Syrrx, a company specializing in high-throughput X-ray crystallography, for USD270 million.
In February 2008, Takeda acquired the Japanese operations of Amgen and rights to a dozen of the California biotechnology company's pipeline candidates for the Japanese market. In March 2008, Takeda and Abbott Laboratories announced plans to conclude their 30-year-old joint venture, TAP Pharmaceuticals, that had over USD3 billion in sales in its final year. The split resulted in Abbott acquiring U.S. rights to Lupron and the drug's support staff. On the other hand, Takeda received rights to Prevacid and TAP's pipeline candidates. The move also increased Takeda's headcount by 3,000 employees. In April 2008, Takeda announced that it was acquiring Millennium Pharmaceuticals of Cambridge, Massachusetts, a company specializing in cancer drug research, for USD8.8 billion. The acquisition brought in Velcade, a drug indicated for hematological malignancies, as well as a portfolio of pipeline candidates in the oncology, inflammation, and cardiovascular therapeutic areas. Millennium now operates as an independent subsidiary, "Millennium: The Takeda Oncology Company."  In May 2008, the company licensed non-exclusively the RNAi technology platform developed by Alnylam Pharmaceuticals, creating a potentially long-term partnership between the companies.
On April 11, 2012, Takeda Pharmaceutical and URL Pharma announced that Takeda would acquire URL Pharma, then run by the founder's son Richard Roberts, for USD800 million. The acquisition was completed by June 4, 2012. On 25 May 2012, Takeda announced the purchase of Brazilian pharmaceutical company Multilab by R$540 million.
On 26 September 2014, Takeda announced it would team up with BioMotiv with the stated aim of identifying and developing new compounds over a five-year period, worth approximately USD25 million. On 30 September 2014, Takeda announced its intention to expand a collaboration with MacroGenics, valued up to USD1.6 billion. The collaboration will focus on the co-development of the preclinical autoimmune compound MGD010. MGD010 is a therapy which targets the B-cell surface proteins CD32B and CD79B, and is indicated for lupus and rheumatoid arthritis.
In 2015, Takeda sold its respiratory drugs business to the Swedish-British AstraZeneca for $575 million (about £383 million), a deal that included roflumilast and ciclesonide. On November 20, 2015, the U.S. Food and Drug Administration approved Ixazomib developed by Takeda for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma after at least one prior therapy.
On December 2, 2016, the company spun out its neuroscience research division into Cerevance, a join venture along with Lightstone Ventures.
In January 2017, Takeda announced it would acquire Ariad Pharmaceuticals for $5.2 billion, expanding the company's oncology and hematology divisions. The acquisition of Ariad closed on February 16th, 2017. 
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
|Takeda Pharmaceutical Company||
Takeda operates two primary bases in Japan in Osaka and Tokyo. Its United States subsidiary is based in Deerfield, Illinois, and all Global Operations outside Japan and U.S. are based in Opfikon (Zurich), Switzerland. The company maintains research and development sites in Osaka and Shonan, Japan; San Diego and Cambridge, United States; London, United Kingdom; and Singapore.
In April 2015 Takeda agreed to pay a settlement of $2.37 billion to an estimated 9,000 people who submitted claims alleging that pioglitazone was responsible for giving them bladder cancer. In 2014, a plaintiff was awarded $9 billion in punitive damages after a federal court found Takeda hid the cancer risks of their diabetes medicine, but the amount was later reduced to $37 million by a judge who deemed the charge excessive.
- Chris Gallagher (2015-03-15). Muralikumar Anantharaman, ed. "Japan drugmaker Takeda says Christophe Weber to become CEO April 1". Reuters. Retrieved 2015-04-20.
- "Financial Results for Fiscal 2012" (PDF). Takeda Pharmaceutical Company Limited. 2013-05-09. Retrieved 2013-06-13.
- "Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes". Newsblaze.com. 2009-08-28. Retrieved 2010-09-18.
- "FAQ." Takeda Pharmaceutical Company. Retrieved on 2011-02-02. "Q : Where is Takeda located? A : The Head Office is located in Osaka, Japan, and the Tokyo Head Office is located in Tokyo, Japan."
- "Overview." Takeda Pharmaceutical Company. Retrieved on 2011-02-02. "Headquarters Head Office 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645" and "Tokyo Head Office 12-10, Nihonbashi 2-chome, Chuo-ku, Tokyo 103-8668"
- "TAP Pharmaceutical Products, Inc.: Private Company Information - BusinessWeek". Investing.businessweek.com. 2008-04-30. Retrieved 2010-09-18.
- Decker, Susan (2009-07-06). "Takeda Sues Torrent to Stop Generic Copy of Actos Diabetes Pill". Bloomberg. Retrieved 2010-09-18.
- Somers, Terri (2005-02-08). "Japanese drug giant taking over Syrrx here | The San Diego Union-Tribune". Signonsandiego.com. Retrieved 2010-09-18.
- "Takeda, Amgen in exclusive tie-up for Japanese market". MarketWatch. 2008-02-04. Retrieved 2010-09-18.
- Marrazzo, Amanda (2008-05-15). "Featured Articles From The Chicago Tribune". Archives.chicagotribune.com. Retrieved 2010-09-18.
- "MILLENNIUM: The Takeda Oncology Company | About Millennium | Our History". Mlnm.com. Retrieved 2010-09-18.
- staff (2008-06-15). "Takeda Signs On as Alnylam's Asian Partner for $150M Upfront". Genetic Engineering & Biotechnology News (print). Mary Ann Liebert, Inc. p. 14.
- Limited, Takeda Pharmaceutical Company. "Takeda completes acquisition and names new CEO of Nycomed - Takeda Pharmaceutical Company Limited".
- Limited, Takeda Pharmaceutical Company. "Takeda Completes Acquisition of URL Pharma, Inc. - Takeda Pharmaceutical Company Limited".
- Hirschler, Ben (2012-05-25). "Farmacêutica Takeda comprará Multilab por até R$ 540 mi". Grupo Abril (in Portuguese). Exame. Retrieved 2013-01-27.
- "Takeda, BioMotiv Launch $25M Drug Development Partnership". Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. 2014-09-26. Retrieved 2015-04-23.
- "Takeda, MacroGenics Launch Up to $1.6B Expansion of DART Collaboration". Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. 2014-09-30. Retrieved 2015-04-23.
- Julia Bradshaw for The Daily Telegraph, 16 December 2015. AstraZeneca to buy Takeda's lung business for £383m.Accessed: 17 December 2015.
- "Press Announcements — FDA approves Ninlaro, new oral medication to treat multiple myeloma". U.S. Food and Drug Administration. Retrieved 24 April 2016.
- "Locations | Worldwide | Takeda Pharmaceutical Company Limited". Takedaism.com. Retrieved 2010-09-18.
- "Takeda Agrees to Pay $2.4 Billion to Settle Suits Over Cancer Risk of Actos". The New York Times. 29 April 2015.
- Feeley, Jef; Matsuyama, Kanoko (9 April 2014). "Takeda, Lilly Jury Awards $9 Billion Over Actos Risks" – via www.bloomberg.com.
- "Japan's Takeda Agrees To $2.4B Settlement In Diabetes Drug Actos Lawsuit Over Cancer Risk Allegations". 29 April 2015.
Media related to Takeda Pharmaceutical Company at Wikimedia Commons